1. Home
  2. WEN vs OMER Comparison

WEN vs OMER Comparison

Compare WEN & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wendy's Company (The)

WEN

Wendy's Company (The)

N/A

Current Price

$8.61

Market Cap

1.5B

ML Signal

N/A

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$13.38

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WEN
OMER
Founded
1969
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.2B
IPO Year
2001
2008

Fundamental Metrics

Financial Performance
Metric
WEN
OMER
Price
$8.61
$13.38
Analyst Decision
Hold
Buy
Analyst Count
20
3
Target Price
$8.04
★ $27.50
AVG Volume (30 Days)
★ 7.3M
1.2M
Earning Date
11-05-2026
11-16-2026
Dividend Yield
★ 3.26%
N/A
EPS Growth
N/A
★ 98.15
EPS
★ 0.37
0.13
Revenue
★ $2,176,891,000.00
$29,868,000.00
Revenue This Year
$1.71
N/A
Revenue Next Year
$0.57
$66.13
P/E Ratio
★ $23.24
$107.77
Revenue Growth
★ N/A
N/A
52 Week Low
$5.94
$6.70
52 Week High
$9.45
$21.24

Technical Indicators

Market Signals
Indicator
WEN
OMER
Relative Strength Index (RSI) 68.64 31.39
Support Level $6.62 $9.45
Resistance Level $9.30 $19.68
Average True Range (ATR) 0.34 0.90
MACD 0.07 -0.44
Stochastic Oscillator 77.57 12.03

Price Performance

Historical Comparison
WEN
OMER

About WEN Wendy's Company (The)

The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: